Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ

The Plasmodium falciparum circumsporozoite (CS) protein-based pre-erythrocytic stage vaccine, RTS,S, induces a high level of protection against experimental sporozoite challenge. The immune mechanisms that constitute protection are only partially understood, but are presumed to rely on Abs and T cel...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of immunology (1950) Vol. 171; no. 12; pp. 6961 - 6967
Main Authors Sun, Peifang, Schwenk, Robert, White, Katherine, Stoute, Jose A., Cohen, Joe, Ballou, W. Ripley, Voss, Gerald, Kester, Kent E., Heppner, D. Gray, Krzych, Urszula
Format Journal Article
LanguageEnglish
Published United States 15.12.2003
Subjects
Online AccessGet full text
ISSN0022-1767
1550-6606
DOI10.4049/jimmunol.171.12.6961

Cover

More Information
Summary:The Plasmodium falciparum circumsporozoite (CS) protein-based pre-erythrocytic stage vaccine, RTS,S, induces a high level of protection against experimental sporozoite challenge. The immune mechanisms that constitute protection are only partially understood, but are presumed to rely on Abs and T cell responses. In the present study we compared CS protein peptide-recalled IFN-γ reactivity of pre- and RTS,S-immune lymphocytes from 20 subjects vaccinated with RTS,S. We observed elevated IFN-γ in subjects protected by RTS,S; moreover, both CD4+ and CD8+ T cells produced IFN-γ in response to CS protein peptides. Significantly, protracted protection, albeit observed only in two of seven subjects, was associated with sustained IFN-γ response. This is the first study demonstrating correlation in a controlled Plasmodia sporozoite challenge study between protection induced by a recombinant malaria vaccine and Ag-specific T cell responses. Field-based malaria vaccine studies are in progress to validate the establishment of this cellular response as a possible in vitro correlate of protective immunity to exo-erythrocytic stage malaria vaccines.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0022-1767
1550-6606
DOI:10.4049/jimmunol.171.12.6961